Revagenix Taps Scientific Architect as CSO, Advances Lead Drug into Clinic

SAN FRANCISCO, CA – July 21, 2026 – In a move signaling a new phase of clinical and strategic growth, biopharmaceutical firm Revagenix, Inc. has elevated Dr. Peter Smith to Chief Scientific Officer. The promotion coincides with a critical milestone for the company: the entry of its lead program, Rev-56, into Phase 1 clinical trials for non-cystic fibrosis bronchiectasis (NCFB), a debilitating chronic respiratory disease.

This dual development positions Revagenix, a company launched in 2020, to transition from a preclinical entity to a clinical-stage player. With a seasoned drug hunter at the scientific helm and its first asset under clinical evaluation, the firm is sharpening its focus on delivering what it calls “purpose-built medicines” for chronic conditions where patient needs remain profoundly unmet.

A New Architect for a Patient-Centric Pipeline

Dr. Smith’s promotion is a clear endorsement of his role in shaping Revagenix’s foundational science. With over fifteen years of experience, his track record demonstrates a rare ability to shepherd novel therapeutics from the lab bench to human trials. Before joining Revagenix in 2022, he spent eight years at biotech giant Genentech, where he led research teams that successfully advanced two new small-molecule drugs into Phase 1 studies. His entrepreneurial credentials include co-founding RQx Pharmaceuticals, whose lead program was compelling enough to be in-licensed by Genentech in 2013.

At Revagenix, Dr. Smith was the key strategist behind Rev-56, guiding it from early chemistry through the rigorous preclinical work required for clinical entry. “As a holistic scientific strategist, Peter successfully guided our Rev-56 program... shaping not only the science but the real-world design and delivery choices that make it purpose-built for NCFB patients,” said Ryan Cirz, Ph.D., Chief Executive Officer of Revagenix. “His promotion to CSO is a direct reflection of his exceptional leadership and contributions to date.”

In his new capacity, Dr. Smith will oversee the clinical journey of Rev-56 while simultaneously spearheading the expansion of the company’s pipeline. This dual mandate is central to the company’s strategy of building lasting value. “I’m honored to step into the CSO role at this pivotal moment for Revagenix as Rev-56 enters the clinic,” said Dr. Smith. His focus remains squarely on the patient experience, a philosophy he intends to apply across the company’s future programs.

Targeting a Neglected Disease with Purpose-Built Design

Revagenix’s initial focus, non-cystic fibrosis bronchiectasis (NCFB), exemplifies the type of challenge it aims to solve. NCFB is a chronic condition where the airways in the lungs become permanently widened, leading to a buildup of excess mucus and making patients highly susceptible to recurrent infections. Affecting an estimated 350,000 to 500,000 adults in the United States alone, the disease imposes a significant daily burden, punctuated by severe exacerbations that degrade lung function and quality of life over time.

For decades, NCFB lacked any specifically approved therapies, forcing clinicians to manage symptoms with a complex cocktail of antibiotics, airway clearance techniques, and anti-inflammatories. The difficulty of this regimen is reflected in startlingly low patient adherence rates, which some studies estimate to be as low as 16% for all prescribed treatments. This gap between prescribed care and real-world application is precisely what Revagenix aims to bridge.

“Tolerability and convenience were core design criteria throughout our optimization program — because in NCFB, adherence is critical to protecting lung function and quality of life over time,” Dr. Smith explained. Rev-56, an inhaled therapy delivered directly to the site of disease, was engineered with this principle in mind. The newly initiated Phase 1 trial will evaluate the safety and tolerability of Rev-56 in healthy adults and in NCFB patients with chronic Pseudomonas aeruginosa infection, a key driver of disease progression. The company is also advancing a dry-powder formulation, which could further enhance convenience and improve adherence for patients managing this lifelong condition.

Navigating a Growing Market with Strong Backing

The strategic timing of Revagenix’s clinical entry is noteworthy. The NCFB market is awakening, with analysts projecting its value in major markets to surge from under $2 billion in 2025 to over $7 billion by 2036. This growth is fueled by greater awareness and the recent arrival of the first-ever FDA-approved therapy for NCFB, Insmed’s brensocatib, in 2025. While this introduces a formidable competitor, it also validates the significant commercial opportunity for effective, well-tolerated treatments.

Revagenix is not entering this evolving landscape alone. The company is supported by a syndicate of sophisticated life science investors and government bodies. Its backers include Tenmile, an Australian venture capital firm, and Novo Holdings, which invested via its REPAIR Impact Fund—a specialized fund dedicated to combating antimicrobial resistance. This targeted investment underscores the scientific credibility of Revagenix’s approach. Furthermore, the development of Rev-56 is supported by federal funding from the U.S. National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), which provides non-dilutive capital and external validation.

This robust financial and institutional backing, totaling $14 million raised to date, provides the company with the runway needed to navigate the capital-intensive world of clinical development. It allows the leadership team to focus on executing its scientific strategy: proving the value of Rev-56 in the clinic while laying the groundwork for a broader pipeline of medicines designed for the realities of chronic disease management.